Pelvic Exenteration for Recurrent and Persistent Cervical Cancer  

作　　者：Lei Li Shui-Qing Ma Xian-Jie Tan Sen Zhong Ming Wu 

机构地区：[1]Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China

出　　处：《Chinese Medical Journal》2018年第13期1541-1548,共8页中华医学杂志（英文版）

摘　　要：Background： Pelvic exenteration （PE） for primary and recurrent cervical cancer has resulted in favorable survival outcomes, but there are controversies about specific prognosis factors, and up to now, there have been no published reports from China. This study aimed to share our experiences of PE, which were performed in a single institution. Methods： Frorn January 2009 to January 2016, 38 patients with recurrent or persistent cervical cancer were included in the study, and they were followed up until January 2017. Epidemiological and clinicopathological characteristics of patients were compared for survival outcornes in univariate and Cox hazard regression analysis. Results： There were thirty-one and seven patients with recurrent and persistent cervical cancer, respectively. The median age of patients was 45 years （range 29 65 years）. Total, anterior, and posterior PE consisted of 52.6%, 28.9%, and 18.4% of cases, respectively. Early and late complications occurred in 21 （55.3%） patients and 15 （39.5%） patients, respectively. Two （5.3%） patients died due to complications related to surgeries within 3 months after PE. The median overall survival （OS） and disease-free survival （DFS） were 28.5 months （range 9-96 months） and 23 rnonths （range 4.-96 months）, respectively, and 5-year OS and DFS were 48% and 40%, respectively. Cox hazard regression analysis showed that, the margin status of the incision and mesorectal lymph node status were independent risk factors liar OS and DFS. Conclusion： In our patients with rect.rrent and persistent cervical cancer, the practice of PE might achieve favorable survival outcomes. Trial Registration： ClinicalTrials.gov, NCT03291275; https：//clinicaltrials.gov/ct2/show/NCT03291275？term-NCT03291275＆rank = 1.Background： Pelvic exenteration （PE） for primary and recurrent cervical cancer has resulted in favorable survival outcomes, but there are controversies about specific prognosis factors, and up to now, there have been no published reports from China. This study aimed to share our experiences of PE, which were performed in a single institution. Methods： Frorn January 2009 to January 2016, 38 patients with recurrent or persistent cervical cancer were included in the study, and they were followed up until January 2017. Epidemiological and clinicopathological characteristics of patients were compared for survival outcornes in univariate and Cox hazard regression analysis. Results： There were thirty-one and seven patients with recurrent and persistent cervical cancer, respectively. The median age of patients was 45 years （range 29 65 years）. Total, anterior, and posterior PE consisted of 52.6%, 28.9%, and 18.4% of cases, respectively. Early and late complications occurred in 21 （55.3%） patients and 15 （39.5%） patients, respectively. Two （5.3%） patients died due to complications related to surgeries within 3 months after PE. The median overall survival （OS） and disease-free survival （DFS） were 28.5 months （range 9-96 months） and 23 rnonths （range 4.-96 months）, respectively, and 5-year OS and DFS were 48% and 40%, respectively. Cox hazard regression analysis showed that, the margin status of the incision and mesorectal lymph node status were independent risk factors liar OS and DFS. Conclusion： In our patients with rect.rrent and persistent cervical cancer, the practice of PE might achieve favorable survival outcomes. Trial Registration： ClinicalTrials.gov, NCT03291275; https：//clinicaltrials.gov/ct2/show/NCT03291275？term-NCT03291275＆rank = 1.

关 键 词：Cervical Cancer Pelvic Exenteration SURVIVAL 

分 类 号：R737.33[医药卫生—肿瘤]